Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

NCT05488132 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia, in Relapse

Interventions

DRUG: anti-siglec-6 CAR-T cell therapy

Sponsor

Xuzhou Medical University